Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doravirine/lamivudine/tenofovir disoproxil fumarate - Merck & Co

Next Previous
Drug Profile

Doravirine/lamivudine/tenofovir disoproxil fumarate - Merck & Co

Alternative Names: DELSTRIGO; DOR/3TC/TDF; MK-1439/lamivudine/tenofovir disoproxil fumarate; MK-1439A

Latest Information Update: 10 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Developer Merck Sharp & Dohme; National Institute of Allergy and Infectious Diseases
  • Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Nitriles; Phosphonic acids; Purines; Pyridones; Pyrimidine nucleosides; Small molecules; Triazoles
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 27 Jan 2025 Merck Sharp & Dohme initiates enrolment in the phase-III ELDORADO trial for HIV-1 infections (Treatment-naive) in France (PO) (NCT06203132)
  • 07 Sep 2023 Merck Sharp & Dohm completes the phase III DRIVE-AHEAD phase III trial in HIV-1 infections (Treatment-naive) in USA, Australia, Belgium, Canada, Chile, Colombia, Denmark, Germany, Guatemala, Hondura, Israel, Mexico, New Zealand, Peru, Portugal, Puerto Rico, Russia, South Africa, Spain, Switzerland, Taiwan, Thailand, the Netherlands and United Kingdom (PO) (NCT02403674) (EudraCT2014-003382-17)
  • 05 Sep 2023 Merck Sharp & Dohm completes the phase III DRIVE-SHIFT trial in HIV-1 infections (Treatment-experienced) in USA, Argentina, Austria, Belgium, Canada, Denmark, Germany, Guatemala, Peru, Poland, Puerto Rico, Spain, Switzerland, Italy and the United Kingdom (PO) (NCT02397096) (EudraCT2014-005550-18)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top